Home Cart Sign in  
Chemical Structure| 22888-70-6 Chemical Structure| 22888-70-6

Structure of Silybin A
CAS No.: 22888-70-6

Chemical Structure| 22888-70-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Silibinin is an antioxidant which shows inhibition of p-glycoprotein-mediated cellular efflux and obvious stability of liver cell membrane. Silibinin can be extracted from the herb of Silybum marianum (L.) Gaertn.

Synonyms: Silibinin A; Silybin; Silymarine I

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Silybin A

CAS No. :22888-70-6
Formula : C25H22O10
M.W : 482.44
SMILES Code : O=C1[C@H](O)[C@@H](C2=CC=C(O[C@H](CO)[C@@H](C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
Synonyms :
Silibinin A; Silybin; Silymarine I
MDL No. :MFCD00872186
InChI Key :SEBFKMXJBCUCAI-HKTJVKLFSA-N
Pubchem ID :31553

Safety of Silybin A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SKOV3 cells 100 µM 24 hours SIL inhibits phosphorylation of ERK and Akt. Cancer Sci. 2022 Sep;113(9):3032-3043.
HK2 cells 50 µM 24 hours To evaluate the effect of Silybin A on cisplatin-induced mitochondrial dysfunction and apoptosis in HK2 cells. Results showed that Silybin A improved mitochondrial function, reduced ROS production, and decreased apoptosis. Front Pharmacol. 2017 Apr 5;8:178.
Primary monocytes 20 µM 24 hours To investigate the effects of Silybin A on lipid metabolism in primary monocytes, results showed Silybin A had no significant effect on triglyceride levels. Theranostics. 2025 Jan 6;15(5):2006-2034.
HepaRG cells 20 µM 24 hours To investigate the effects of Silybin A on lipid metabolism in HepaRG cells, results showed Silybin A reduced lipid droplet content. Theranostics. 2025 Jan 6;15(5):2006-2034.
HepG2 cells 20 µM 24 hours To investigate the effects of Silybin A on lipid metabolism in HepG2 cells, results showed Silybin A decreased triglyceride levels and increased phospholipid content. Theranostics. 2025 Jan 6;15(5):2006-2034.
HepG2 cells 2, 10, 50 µM 24 hours To evaluate the effect of Silybin on P450s activity under TG-induced ER stress, results showed that Silybin reversed the inhibition of P450s activity by TG Acta Pharmacol Sin. 2023 Jan;44(1):133-144.
LX-2 cells 20 μg/mL 24 hours Evaluate anti-hepatic fibrosis efficacy by inhibiting collagen I secretion. Results showed that NS-SLB and NS-SLB-HC significantly inhibited collagen I secretion. Int J Nanomedicine. 2023 Sep 12;18:5197-5211.
HK2 cells 50 µM 24 hours To evaluate the effect of Silybin A on cisplatin-induced mitochondrial dysfunction and apoptosis in HK2 cells. Results showed that Silybin A improved mitochondrial function, reduced ROS production, and decreased apoptosis. Front Pharmacol. 2017 Apr 5;8:178.
OVCAR3 cells 50 µM and 100 µM 24 hours and 48 hours SIL inhibits cell proliferation and induces morphological changes by increasing ROS levels. Cancer Sci. 2022 Sep;113(9):3032-3043.
RAW264.7 mouse macrophages 50 and 100 µM 3 hours Inhibited LPS-induced NF-κB phosphorylation and nuclear translocation, reduced TNF-α and IL-1β mRNA/protein expression Int J Mol Med. 2017 May;39(5):1111-1118.
RAW 264.7 cells 1.0 μg/mL to 50 μg/mL 48 hours Evaluate cytotoxicity. Results showed that SLB displayed low toxicity against RAW 264.7 cells at concentrations up to 50 μg/mL. Int J Nanomedicine. 2023 Sep 12;18:5197-5211.
LO2 cells 1.0 μg/mL to 50 μg/mL 48 hours Evaluate cytotoxicity. Results showed that SLB displayed low toxicity against LO2 cells at concentrations up to 50 μg/mL. Int J Nanomedicine. 2023 Sep 12;18:5197-5211.
HepG2 cells 1.0 μg/mL to 50 μg/mL 48 hours Evaluate cytotoxicity. Results showed that SLB displayed low toxicity against HepG2 cells at concentrations up to 50 μg/mL. Int J Nanomedicine. 2023 Sep 12;18:5197-5211.
HepG2 cells 68 µM (IC50) 72 hours To study the effect of Silybin on HepG2 cell growth, results showed that Silybin inhibited cell growth by blocking the cell cycle in G1 phase and activating programmed cell death. Int J Mol Sci. 2019 May 3;20(9):2190.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Ovarian cancer xenograft model Oral gavage 100 mg/kg Once daily for 6 weeks SIL controls cancer tissue growth by inhibiting IDH1 expression. Cancer Sci. 2022 Sep;113(9):3032-3043.
SV129 mice Cisplatin-induced acute kidney injury model Intragastric administration 200 mg/kg Once daily for 7 days before and 3 days after cisplatin injection To evaluate the protective effect of Silybin A on cisplatin-induced acute kidney injury. Results showed that Silybin A significantly reduced blood urea nitrogen levels, improved renal tubular injury, and enhanced mitochondrial function in a SIRT3-dependent manner. Front Pharmacol. 2017 Apr 5;8:178.
C57BL/6 mice Healthy mice Intraperitoneal injection 200 mg/kg Three times (at 0, 12, and 24 h), sacrificed after 37 h To investigate the effects of Silybin A on liver lipid metabolism in mice, results showed Silybin A increased hepatic phospholipid content and decreased triglyceride levels. Theranostics. 2025 Jan 6;15(5):2006-2034.
C57BL/6J mice Renal ischemia-reperfusion injury (IRI)-induced acute kidney injury (AKI) model Intraperitoneal injection 25 mg/kg, 50 mg/kg, 100 mg/kg Once daily for 3 consecutive days To evaluate the protective effect of Silybin A on IRI-AKI, results showed that Silybin A significantly improved renal dysfunction and pathological damage, and inhibited ferroptosis Redox Biol. 2024 Nov;77:103360.
C57/BL6 mice LPS-induced acute lung injury model Intragastric 50 and 100 mg/kg Once daily for 3 consecutive days Attenuated LPS-induced pulmonary inflammatory cell infiltration, edema, and pathological damage; reduced TNF-α/IL-1β levels in BALF and serum; suppressed NF-κB phosphorylation Int J Mol Med. 2017 May;39(5):1111-1118.
C57BL/6 mice High-fat-diet induced nonalcoholic fatty liver disease model Intragastric administration 50, 100 mg/kg/day Once daily for 4 weeks To evaluate the effect of Silybin on P450s activity in HFD-induced NAFLD mice, results showed that Silybin dose-dependently reversed the inhibition of P450s activity by HFD Acta Pharmacol Sin. 2023 Jan;44(1):133-144.
Kunming mice CCl4-induced liver fibrosis model and bile duct ligation (BDL)-induced liver fibrosis model Tail vein injection 8 mg/kg SLB Twice a week for 10 to 12 weeks Evaluate the therapeutic effects of NS-SLB and NS-SLB-HC against hepatic fibrosis. Results showed that both nanosuspensions significantly alleviated hepatic fibrosis, reduced ALT and AST levels, and downregulated TGF-β expression. Int J Nanomedicine. 2023 Sep 12;18:5197-5211.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.07mL

0.41mL

0.21mL

10.36mL

2.07mL

1.04mL

20.73mL

4.15mL

2.07mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories